Surgical Options for Advanced/Metastatic Gastrointestinal Stromal Tumors

被引：8

作者：

Meza, James M. ^{[1
]}

Wong, Sandra L. ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA

来源：

CURRENT PROBLEMS IN CANCER | 2011年 / 35卷 / 05期

关键词：

IMATINIB MESYLATE; TYROSINE KINASE; GIST; SUNITINIB; CHEMOEMBOLIZATION; PROGRESSION; MANAGEMENT; THERAPY; SURGERY; TRIAL;

D O I：

10.1016/j.currproblcancer.2011.09.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：283 / 293

页数：11

共 29 条

[1] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].

Blanke, Charles D. ;

Rankin, Cathryn ;

Demetri, George D. ;

Ryan, Christopher W. ;

von Mehren, Margaret ;

Benjamin, Robert S. ;

Raymond, A. Kevin ;

Bramwell, Vivien H. C. ;

Baker, Laurence H. ;

Maki, Robert G. ;

Tanaka, Michael ;

Hecht, J. Randolph ;

Heinrich, Michael C. ;

Fletcher, Christopher D. M. ;

Crowley, John J. ;

Borden, Ernest C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632

[2] Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial [J].

Blesius, Aurore ;

Cassier, Philippe A. ;

Bertucci, Francois ;

Fayette, Jerome ;

Ray-Coquard, Isabelle ;

Bui, Binh ;

Adenis, Antoine ;

Rios, Maria ;

Cupissol, Didier ;

Perol, David ;

Blay, Jean-Yves ;

Le Cesne, Axel .

BMC CANCER, 2011, 11

[3] Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era [J].

Bonvalot, S. ;

Eldweny, H. ;

Le Pechoux, C. ;

Vanel, D. ;

Terrier, P. ;

Cavalcanti, A. ;

Robert, C. ;

Lassau, N. ;

Le Cesne, A. .

ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (12) :1596-1603

[4]

Dagher R, 2002, CLIN CANCER RES, V8, P3034

[5] Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].

DeMatteo, RP ;

Lewis, JJ ;

Leung, D ;

Mudan, SS ;

Woodruff, JM ;

Brennan, MF .

ANNALS OF SURGERY, 2000, 231 (01) :51-58

[6] Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [J].

Demetri, G. D. ;

Huang, X. ;

Garrett, C. R. ;

Schoffski, P. ;

Blackstein, M. E. ;

Shah, M. H. ;

Verweij, J. ;

Tassell, V. ;

Baum, C. M. ;

Casali, P. G. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[7] Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571) [J].

Demetri, GD .

EUROPEAN JOURNAL OF CANCER, 2002, 38 :S52-S59

[8] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[9]

Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1

[10] Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665 [J].

Eisenberg, Burton L. ;

Harris, Jonathan ;

Blanke, Charles D. ;

Demetri, George D. ;

Heinrich, Michael C. ;

Watson, James C. ;

Hoffman, John P. ;

Okuno, Scott ;

Kane, John M. ;

von Mehren, Margaret .

JOURNAL OF SURGICAL ONCOLOGY, 2009, 99 (01) :42-47

← 1 2 3 →